We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
-3.3%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$130M
AUM Growth
+$22.9M
Cap. Flow
+$39.4M
Cap. Flow %
30.35%
Top 10 Hldgs %
59.82%
Holding
41
New
8
Increased
13
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
DCTH icon
Delcath Systems
DCTH
+$10.2M
2
ABEO icon
Abeona Therapeutics
ABEO
+$8.93M
3
CLRB icon
Cellectar Biosciences
CLRB
+$6.67M
4
OCUL icon
Ocular Therapeutix
OCUL
+$4.63M
5
NSPR icon
InspireMD
NSPR
+$4.28M

Top Sells

Rank Stock Value
1
VERU icon
Veru
VERU
+$2.09M
2
TVRD
Tvardi Therapeutics
TVRD
+$1.41M
3
UNCY icon
Unicycive Therapeutics
UNCY
+$303K
4
LYRA
LYRA THERAPEUTICS INC
LYRA
+$248K
5
KPRX icon
Kiora Pharmaceuticals
KPRX
+$5

Sector Composition

Rank Sector Weight
1 Healthcare 97.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$416M
$15.5M 11.95%
2,650,389
+1,611,561
+155% +$10.2M
MYO icon
2
Myomo
MYO
$38.6M
$8.55M 6.58%
2,664,999
+217,259
+9% +$737K
MDWD icon
3
MediWound
MDWD
$181M
$7.97M 6.13%
513,490
+27,500
+6% +$455K
OPTN
4
DELISTED
OptiNose
OPTN
$7.85M 6.04%
503,143
+200,377
+66% +$3.36M
ABEO icon
5
Abeona Therapeutics
ABEO
$369M
$7.42M 5.71%
+1,750,000
New +$8.93M
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.45B
$7.02M 5.4%
3,120,170
+300,000
+11% +$605K
CLRB icon
7
Cellectar Biosciences
CLRB
$20.2M
$6.76M 5.21%
90,187
+69,471
+335% +$6.67M
NSPR icon
8
InspireMD
NSPR
$31.5M
$6.27M 4.83%
2,513,641
+1,827,579
+266% +$4.28M
HELP
9
Cybin Inc
HELP
$505M
$5.23M 4.02%
507,895
+140,527
+38% +$1.84M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.85B
$5.13M 3.95%
+750,000
New +$4.63M
ABVX
11
Abivax
ABVX
$10.8B
$5M 3.85%
378,416
– –
PROF
12
Profound Medical
PROF
$263M
$4.47M 3.44%
533,333
– –
CMPS
13
Compass Pathways
CMPS
$1.56B
$4.43M 3.41%
734,000
– –
TRVI icon
14
Trevi Therapeutics
TRVI
$2.61B
$4.15M 3.19%
1,391,577
+465,561
+50% +$1.29M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$3.98M 3.06%
337,985
+50,000
+17% +$584K
VRDN icon
16
Viridian Therapeutics
VRDN
$2.2B
$3.9M 3%
300,000
– –
VRNA
17
DELISTED
Verona Pharma
VRNA
$3.62M 2.78%
250,000
– –
CLSD
18
DELISTED
Clearside Biomedical
CLSD
$3.37M 2.59%
172,840
– –
OTLK icon
19
Outlook Therapeutics
OTLK
$194M
$3.32M 2.56%
450,000
+138,225
+44% +$1.11M
VERU icon
20
Veru
VERU
$35.6M
$2.27M 1.75%
269,600
-180,400
-40% -$2.09M
PYPD icon
21
PolyPid
PYPD
$83.8M
$1.79M 1.38%
416,800
+1,000
+0.2% +$4.47K
FLNA
22
PUT
Filana Therapeutics
FLNA
$46.4M
$1.3M 1%
+3,673
New +$77.4K
RZLT icon
23
Rezolute
RZLT
$470M
$1.07M 0.83%
250,000
+50,000
+25% +$172K
KPRX icon
24
Kiora Pharmaceuticals
KPRX
$11.3M
$1.07M 0.83%
255,555
-1
-0% -$5
XBI icon
25
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$1.04M 0.8%
22,403
-27,597
-55% -$2.47M
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Rosalind Advisors held 41 positions worth $130M, up 21% from $107M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Rosalind Advisors deployed $39.4M of net new capital in Q2 2024, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was Abeona Therapeutics: 1,750,000 shares worth $7.42M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Veru, an estimated $2.09M trimmed.

  • Rosalind Advisors's largest Q2 2024 buy was Abeona Therapeutics: 1,750,000 shares worth $7.42M.
  • Rosalind Advisors added most to Delcath Systems in Q2 2024, an estimated $10.2M increase.
  • Rosalind Advisors's biggest Q2 2024 reduction was Veru, cutting an estimated $2.09M.
  • Rosalind Advisors fully exited Tvardi Therapeutics in Q2 2024, selling an estimated $1.41M.
  • Rosalind Advisors's ten largest holdings make up 60% of its $130M portfolio in Q2 2024.
  • Rosalind Advisors opened 8 new positions and closed 2 in Q2 2024.
  • Rosalind Advisors's portfolio value rose 21% quarter-over-quarter to $130M.

Based on Rosalind Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.